All In Biotech

NDA 014602 · Organon

Celestone Soluspan

Betamethasone Acetate, Betamethasone Sodium Phosphate · Injection

Novel

Last checked: Nov 19, 2026Latest source record: Jul 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1965

Mar 3, 1965

Approved uses

1

Original approval plus efficacy supplements

Registered trials

399

91 Phase 3, 36 recruiting

FAERS reports

397

177 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 24, 2026.

INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of CELESTONE ® SOLUSPAN ® Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 3, 1965 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • CELESTONE SOLUSPAN · BETAMETHASONE ACETATE 3MG/ML; BETAMETHASONE SODIUM PHOSPHATE EQ 3MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Betamethasone" as an intervention, any sponsor and status, largest first.

All 399 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • maternal exposure during pregnancy122
  • product use in unapproved indication28
  • drug ineffective21
  • exposure during pregnancy20
  • no adverse event20
  • pain17
  • anxiety15
  • headache14
  • dizziness13
  • fatigue12
  • insomnia12
  • anaphylactic reaction11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200519
200610
20074
20089
200916
20106
20117
20125
201316
201414
201511
201641
201724
201830
201940
202042
202137
202227
202314
20249
20253
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,269 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.